Sentinel lymph node detection using fluorescein and blue light-emitting diodes in patients with breast carcinoma: A single-center prospective study

Research output: Contribution to journalArticle

Abstract

Background: Sentinel lymph node (SLN) biopsy is an essential procedure for lymph node staging in patients with breast carcinoma. Technetium-99m-labelled nanocolloid ( 99m Tc) is the most accurate and widely used lymphatic mapping agent; however, there are concerns pertaining to the associated exposure to radiation. Studies focusing on new agents are required. We aimed to evaluate the feasibility and safety of SLN detection using fluorescein and blue light-emitting diodes (LEDs) in breast carcinoma patients. Methods: In this prospective study, a total of 61 patients with breast carcinoma, requiring SLN biopsy, were enrolled. Both fluorescein and 99m Tc were intradermally injected into the areola of the affected breast of each patient. SLNs stained with fluorescein were detected using blue LED light first, and then, any remaining SLNs were detected using a gamma detection probe. The detection rate was analyzed, and the presence of complications was investigated. Results: SLNs dyed with fluorescein using blue LED light were visualized in 57 of 61 patients (93.4%). None of the patients experienced complications related to the use of fluorescein or blue LED light. Conclusions: The detection of SLNs using fluorescein and blue LED light was feasible and safe in patients with breast carcinoma. This technique involves the use of visible light, allowing for SLNs to be viewed with the naked eye, and is quantifiable, easy to use, and economical.

Original languageEnglish
JournalAsian Journal of Surgery
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Fluorescein
Prospective Studies
Breast Neoplasms
Light
Sentinel Lymph Node Biopsy
Nipples
Technetium
Sentinel Lymph Node
Breast
Lymph Nodes
Safety

Keywords

  • Breast carcinoma
  • Fluorescein
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Surgery

Cite this

@article{bea551cf0b8342bbbdd860a0d2b7f100,
title = "Sentinel lymph node detection using fluorescein and blue light-emitting diodes in patients with breast carcinoma: A single-center prospective study",
abstract = "Background: Sentinel lymph node (SLN) biopsy is an essential procedure for lymph node staging in patients with breast carcinoma. Technetium-99m-labelled nanocolloid ( 99m Tc) is the most accurate and widely used lymphatic mapping agent; however, there are concerns pertaining to the associated exposure to radiation. Studies focusing on new agents are required. We aimed to evaluate the feasibility and safety of SLN detection using fluorescein and blue light-emitting diodes (LEDs) in breast carcinoma patients. Methods: In this prospective study, a total of 61 patients with breast carcinoma, requiring SLN biopsy, were enrolled. Both fluorescein and 99m Tc were intradermally injected into the areola of the affected breast of each patient. SLNs stained with fluorescein were detected using blue LED light first, and then, any remaining SLNs were detected using a gamma detection probe. The detection rate was analyzed, and the presence of complications was investigated. Results: SLNs dyed with fluorescein using blue LED light were visualized in 57 of 61 patients (93.4{\%}). None of the patients experienced complications related to the use of fluorescein or blue LED light. Conclusions: The detection of SLNs using fluorescein and blue LED light was feasible and safe in patients with breast carcinoma. This technique involves the use of visible light, allowing for SLNs to be viewed with the naked eye, and is quantifiable, easy to use, and economical.",
keywords = "Breast carcinoma, Fluorescein, Sentinel lymph node biopsy",
author = "Chang, {Young Woo} and Lee, {Hye Yoon} and Lee, {Chang Min} and Jung, {Seung Pil} and Kim, {Woo Young} and Woo, {Sang- Uk} and Lee, {Jae Bok} and Son, {Gil Soo}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.asjsur.2019.03.005",
language = "English",
journal = "Asian Journal of Surgery",
issn = "1015-9584",
publisher = "Elsevier Taiwan LLC",

}

TY - JOUR

T1 - Sentinel lymph node detection using fluorescein and blue light-emitting diodes in patients with breast carcinoma

T2 - A single-center prospective study

AU - Chang, Young Woo

AU - Lee, Hye Yoon

AU - Lee, Chang Min

AU - Jung, Seung Pil

AU - Kim, Woo Young

AU - Woo, Sang- Uk

AU - Lee, Jae Bok

AU - Son, Gil Soo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Sentinel lymph node (SLN) biopsy is an essential procedure for lymph node staging in patients with breast carcinoma. Technetium-99m-labelled nanocolloid ( 99m Tc) is the most accurate and widely used lymphatic mapping agent; however, there are concerns pertaining to the associated exposure to radiation. Studies focusing on new agents are required. We aimed to evaluate the feasibility and safety of SLN detection using fluorescein and blue light-emitting diodes (LEDs) in breast carcinoma patients. Methods: In this prospective study, a total of 61 patients with breast carcinoma, requiring SLN biopsy, were enrolled. Both fluorescein and 99m Tc were intradermally injected into the areola of the affected breast of each patient. SLNs stained with fluorescein were detected using blue LED light first, and then, any remaining SLNs were detected using a gamma detection probe. The detection rate was analyzed, and the presence of complications was investigated. Results: SLNs dyed with fluorescein using blue LED light were visualized in 57 of 61 patients (93.4%). None of the patients experienced complications related to the use of fluorescein or blue LED light. Conclusions: The detection of SLNs using fluorescein and blue LED light was feasible and safe in patients with breast carcinoma. This technique involves the use of visible light, allowing for SLNs to be viewed with the naked eye, and is quantifiable, easy to use, and economical.

AB - Background: Sentinel lymph node (SLN) biopsy is an essential procedure for lymph node staging in patients with breast carcinoma. Technetium-99m-labelled nanocolloid ( 99m Tc) is the most accurate and widely used lymphatic mapping agent; however, there are concerns pertaining to the associated exposure to radiation. Studies focusing on new agents are required. We aimed to evaluate the feasibility and safety of SLN detection using fluorescein and blue light-emitting diodes (LEDs) in breast carcinoma patients. Methods: In this prospective study, a total of 61 patients with breast carcinoma, requiring SLN biopsy, were enrolled. Both fluorescein and 99m Tc were intradermally injected into the areola of the affected breast of each patient. SLNs stained with fluorescein were detected using blue LED light first, and then, any remaining SLNs were detected using a gamma detection probe. The detection rate was analyzed, and the presence of complications was investigated. Results: SLNs dyed with fluorescein using blue LED light were visualized in 57 of 61 patients (93.4%). None of the patients experienced complications related to the use of fluorescein or blue LED light. Conclusions: The detection of SLNs using fluorescein and blue LED light was feasible and safe in patients with breast carcinoma. This technique involves the use of visible light, allowing for SLNs to be viewed with the naked eye, and is quantifiable, easy to use, and economical.

KW - Breast carcinoma

KW - Fluorescein

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=85063049943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063049943&partnerID=8YFLogxK

U2 - 10.1016/j.asjsur.2019.03.005

DO - 10.1016/j.asjsur.2019.03.005

M3 - Article

C2 - 30904399

AN - SCOPUS:85063049943

JO - Asian Journal of Surgery

JF - Asian Journal of Surgery

SN - 1015-9584

ER -